P - Contraindicated in pregnancy
L - Contraindicated in lactation
FI - Food *
Ergotamine is an ergopeptine and part of the ergot family of alkaloids; it is structurally and biochemically closely related to ergoline. It possesses structural similarity to several neurotransmitters, and has biological activity as a vasoconstrictor. It is used medicinally for treatment of acute migraine attacks (sometimes in combination with caffeine), and to induce childbirth and prevent post-partum haemorrhage.
Ergotamine has marked vasoconstrictor effects and partial agonistic action at serotonin receptors. It causes constriction of peripheral and cranial blood vessels and also has powerful oxytocic action on the uterus. It also reduces hyperperfusion in the basilar artery territory.
Absorption
Poorly absorbed from the GI tract (oral, sublingual), decreased further by gastric stasis.
Distribution
Enters breast milk
Metabolism
Extensive hepatic first-pass effect.
Excretion
Via bile (as metabolites), via urine (4%); elimination T1/2 (biphasic): 2 hr (initial phase), 21 hr (terminal phase).
Information Not Available
Muscle cramps, stiffness, tiredness. Numbness and tingling of extremities. Nausea, vomiting, diarrhoea. Ergotism consisting of hypotension and gangrene of extremities, anginal pain and transient tachycardia or bradycardia.
Potentially Fatal: Severe peripheral vasoconstriction, CV disturbances. Due to vascular occlusions causing gangrene, MI, bowel necrosis, renal failure. Simultaneous use of oral contraceptives or β-blockers increases the risk.
Information Not Available
Anaemia. Monitor for signs of ergotism such as numbness or tingling of the extremities.
Vasoconstrictor effects enhanced by sympathomimetic agents e.g. adrenaline. Caffeine potentiates the action of ergotamine.
Potentially Fatal: Administration within 6 hr of taking serotonin agonist may lead to increased and prolonged vasopastic reactions. May have increased risk of peripheral vasoconstriction with β-blockers. Erythromycin increases plasma conc of ergotamine which may lead to ergotism.
Food Interactions
Beverages containing caffeine e.g. tea, cola and coffee.
Oral
Migraine
Adult: As tartrate: 1-2 mg, repeated after 30 minutes if needed. Max:: 6 mg/24 hr, 12 mg/wk. Ensure an interval of at least 4 days between successive 24-hr courses. Not more than 2 courses/mth. May also be given sublingually.
Rectal
Migraine
Adult: As tartrate: 2 mg repeated after 1 hr, if needed. Max: 4 mg/24 hr, 8 mg/wk with an interval of at least 4 days between successive 24-hr courses.
Inhalation
Migraine
Adult: As tartrate: 360 mcg inhaled at the onset of attack and repeated at 5-min intervals, if needed. Max: 6 inhalations/24 hr, 12 inhalations/wk with an interval of at least 4 days between successive 24-hr courses.
May be taken with or without food
Contraindicated in pregnancy.
Category X: Studies in animals or human beings have demonstrated foetal abnormalities or there is evidence of foetal risk based on human experience or both, and the risk of the use of the drug in pregnant women clearly outweighs any possible benefit. The drug is contraindicated in women who are or may become pregnant.
Contraindicated in lactation
Information Not Available
Information Not Available
Severe or uncontrolled hypertension, peripheral vascular disease, pregnancy, lactation, septic conditions, ischaemic heart disease, hyperthyroidism, impaired hepatic or renal function, hypersensitivity, cachexia, collagen disease and fibrotic conditions.
Inhalation
Store below 25°C.
Oral
Store below 25°C.
Rectal
Store below 25°C.
Inhalation
Store below 25°C.
Oral
Store below 25°C.
Rectal
Store below 25°C.
You will hear from us only if the bid amount matches the minimum threshold and intended usage match our vision. You can resubmit another bid.